Cargando…
Adalimumab vs Infliximab in Pediatric Patients With Crohn's Disease: A Propensity Score Analysis and Predictors of Treatment Escalation
INTRODUCTION: Two antitumor necrosis factor therapies (infliximab [IFX] and adalimumab [ADA]) have been approved for the treatment of pediatric Crohn's disease (CD) but have not been compared in head-to-head trials. The aim of this study was to compare the efficacy and safety of ADA and IFX by...
Autores principales: | Bronsky, Jiri, Copova, Ivana, Kazeka, Denis, Lerchova, Tereza, Mitrova, Katarina, Pospisilova, Kristyna, Sulovcova, Miroslava, Zarubova, Kristyna, Hradsky, Ondrej |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9132518/ https://www.ncbi.nlm.nih.gov/pubmed/35363628 http://dx.doi.org/10.14309/ctg.0000000000000490 |
Ejemplares similares
-
Subcutaneous Infliximab in Refractory Crohn’s Disease Patients: A Possible Biobetter?
por: Cerna, Karin, et al.
Publicado: (2023) -
Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn's Disease Patients with Loss of Response to Adalimumab, Especially in Cases without Previous Infliximab Treatment
por: Suzuki, Taketo, et al.
Publicado: (2019) -
The CTLA4 variants may interact with the IL23R- and NOD2-conferred risk in development of Crohn's disease
por: Hradsky, Ondrej, et al.
Publicado: (2010) -
Adalimumab or infliximab: which is better for perianal fistula in Crohn's disease?
por: Im, Jong Pil
Publicado: (2017) -
Infliximab-graded challenge in a patient with Crohn’s disease and adalimumab hypersensitivity
por: Song, Christine H, et al.
Publicado: (2012)